<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160523028008N23</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-06-13</date_registration>
      <primary_sponsor>Hamedan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of levetiracetam and phenobarbital on the control of neonatal seizures</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of efficacy and safety of Levetiracetam and Phenobarbital in controlling neonatal seizures</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-05-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/63092</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are divided into two groups based on a table of random numbers. A random number table is a set of numbers that are produced without a specific pattern or order and in a completely random manner and become a table. In order to use a random number table, the researcher must first predetermine the table to read the numbers for example, up, down, left, or right. Individuals receive a number based on the order of enrollment. Individual numbers are assigned to patients in the intervention group and even numbers are assigned to patients in the control group. assumption, Blinding description: According to randomization, the patient is assigned to one of the control or intervention groups. Drugs that have the same shape are prepared in the ward, drawn in a syringe, and then administered at the patient's bedside. Thus, the form of drug administration will be the same in both groups; based on it, the type of drug can not be determined. Parents of infants and the person who fills out the questionnaires will not know about the prescribed medicine and the form will be filled in according to the assigned code.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Convulsions of newborn.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients are treated with levetiracetam injection (500 mg / 5ml by Estragen Company, Switzerland) at a loading dose of 50 mg/kg and infusion rate of 2 mg/kg/min (within 10 Cc of normal saline) under cardiorespiratory monitoring. If seizures continue with the first dose of levetiracetam, the drug is re-loaded at a dose of 50 mg/kg by the same infusion rate (within 10 cc of normal saline). If the seizure does not stop or returns after 15 minutes, even after the second dose of medication, the treatment groups are changed. If the seizure does not stop or returns after 15 minutes after changing treatment groups, other anticonvulsant drugs are used. Intervention 2: Control group: Patients in the control group are treated with Phenobarbital injection (200mg/ml from Chemidarou company) at a loading dose of 20 mg/kg and at an infusion rate of 1 m/kg/min (within 10 Cc of normal saline) under cardiorespiratory monitoring,If the seizure continues with the first dose, phenobarbital is re-loaded by infusion at a dose of 20 mg per kg at the same rate as before. If the seizure does not stop or returns after 15 minutes, even after the second dose of medication, the treatment groups are changed. If the seizure does not stop or returns after 15 minutes after changing treatment groups, other anticonvulsant drugs are used.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information"</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nader Faraji</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Fatemi Blvd.</address>
        <city>Hamadan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6514845411</zip>
        <telephone>+98 912 248 3658</telephone>
        <email>naderfaraji59@gmail.com</email>
        <affiliation>Hamedan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nader Faraji</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Fatemi Blvd.</address>
        <city>Hamadan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6517838695</zip>
        <telephone>+98 917 332 4977</telephone>
        <email>naderfaraji59@gmail.com</email>
        <affiliation>Hamedan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Gestational age of 36 weeks or more
Weighing 2 kg or more
Occurrence of neonatal seizures between the first day and the 28th day after birth
Consent of the baby's parents or legal guardian</inclusion_criteria>
      <agemin>1 day</agemin>
      <agemax>28 days</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Receiving anti convulsion drugs in the last 72 hours
Seizures due to hypocalcemia, hypoglycemia, hypomagnesemia, and other electrolyte disorders
Serum creatinine level greater than 1.6 mg / dL</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>P90</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Convulsions of newborn</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients are treated with levetiracetam injection (500 mg / 5ml by Estragen Company, Switzerland) at a loading dose of 50 mg/kg and infusion rate of 2 mg/kg/min (within 10 Cc of normal saline) under cardiorespiratory monitoring. If seizures continue with the first dose of levetiracetam, the drug is re-loaded at a dose of 50 mg/kg by the same infusion rate (within 10 cc of normal saline). If the seizure does not stop or returns after 15 minutes, even after the second dose of medication, the treatment groups are changed. If the seizure does not stop or returns after 15 minutes after changing treatment groups, other anticonvulsant drugs are used.</i_keyword>
      <i_keyword>Control group: Patients in the control group are treated with Phenobarbital injection (200mg/ml from Chemidarou company) at a loading dose of 20 mg/kg and at an infusion rate of 1 m/kg/min (within 10 Cc of normal saline) under cardiorespiratory monitoring,If the seizure continues with the first dose, phenobarbital is re-loaded by infusion at a dose of 20 mg per kg at the same rate as before. If the seizure does not stop or returns after 15 minutes, even after the second dose of medication, the treatment groups are changed. If the seizure does not stop or returns after 15 minutes after changing treatment groups, other anticonvulsant drugs are used.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Complete cessation of seizures for 24 hours after medication. Timepoint: In the first 24 hours after medication. Method of measurement: Stopping seizure movements clinically (clinical assessment).</prim_outcome>
      <prim_outcome>Number of doses received to stop seizures. Timepoint: In the first 24 hours after medication. Method of measurement: Patient medical record.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Reduce irritability. Timepoint: Before  and  after intervention. Method of measurement: Daily clinical examination and parental observations.</sec_outcome>
      <sec_outcome>Reduce anorexia. Timepoint: Before and after intervention. Method of measurement: Daily clinical examination and parental observations.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Hamedan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-11-07</approval_date>
        <contact_name>Research Ethic Committee of Hamadan University of Medical Sciences</contact_name>
        <contact_address>Vice-chancellor of Research the Technology, Hamadan University of Medical Sciences, Shahid Fahmide street Hamadan Hamadan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
